Skip to main content
. Author manuscript; available in PMC: 2018 Aug 25.
Published in final edited form as: Leukemia. 2018 Feb 25;32(6):1338–1348. doi: 10.1038/s41375-018-0068-2

Figure 2.

Figure 2

Figure 2

(a) Disease-free survival (DFS) and (b) overall survival (OS) of NPM1-mutated patients stratified by the presence or absence of co-occurring mutations. The blue line represents patients harboring positive predictive marker in addition to the NPM1 mutation (DFS co-mutations: ASXL1, SF1, SMC1A and SRSF2; OS co-mutations: ASXL1, IDH2, SF1 and SRSF2) and red line represents NPM1-mutated patients without those co-mutations. (c) Variant allele fractions (VAFs) of NPM1 and co-occurring mutations in individual patient samples. NPM1 mutations (black bars) were typically observed at lower VAFs than co-occurring mutations (colored bars), suggesting that the NPM1 mutations are later mutational events.